Sinovac Biotech Ltd. is a Chinese biopharmaceutical company that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases.

According to the law firm press release, the lawsuit alleges throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; (2) such conduct would subject Sinovac to heightened regulatory scrutiny; and (3) as a result, Sinovac’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

This case was voluntarily dismissed on September 6, 2017.